BioCentury

Since its inception in 1993, BioCentury, Inc. has earned a global reputation as a top source of valuable insights, analysis, and data for those in the biotechnology and pharmaceutical sectors, as well as investors, academic institutions, and government entities. They focus on key strategic issues that are vital for creating, growing, and maintaining life science companies. BioCentury utilizes a comprehensive multimedia approach that encompasses publications, videos, online data tools, and conferences. This allows them to offer their audience reliable and current information on various topics, including corporate strategies, partnerships, emerging technologies, clinical research, public policies, and financial markets. The editorial and research teams at BioCentury consist of well-respected editors and writers in both business and science. The company is led by a management team with diverse expertise, including international business, publishing, finance, and experience in the biotech and pharmaceutical fields. BioCentury is based in Redwood City, California, with additional offices located in Washington, D.C.; Chicago; and London.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#722082

United States

#316639

Health/Biotechnology and Pharmaceuticals

#303

Traffic sources

Monthly visitors

Articles

FDA’s plans for revamping rare disease regulation

2 days ago | biocentury.com | Steve Usdin

ARTICLE | Politics, Policy & LawCBER Director Prasad says patients ‘deserve cures’ and FDA has an obligation to move fast — but personnel cuts could slow implementation of reforms By Steve Usdin, Washington Editor Eager to demonstrate tangible successes in speeding reviews of new medicines and clearing away outmoded regulatory barriers, FDA Commissioner Marty Makary and senior FDA leaders are prioritizing reforms to the regulatory framework for therapies to treat rare diseases.
Signs of strain and resilience in biotech’s crossover crowd

3 days ago | biocentury.com | Stephen Hansen

ARTICLE | Finance13F filings and venture activity reveal a mixed picture of biotech investor financial health By Stephen Hansen, Director of Biopharma IntelligenceAn analysis of public equity positions held by biopharma’s most active crossover investors suggests thatmost are not in imminent danger. although a few appear to be under financial pressure, with one possibly in more trouble than the others.
Regeneron leans into obesity with Phase II data

4 days ago | biocentury.com | Stephen Hansen

ARTICLE | Product DevelopmentAdditional dose ranging and longer term data necessary to address safety questions By Stephen Hansen, Director of Biopharma IntelligenceRegeneron’s Phase II data for its myostatin and activin A inhibitors is the latest to demonstrate the lean mass lost from GLP-1 therapy and the ability of these mechanisms to improve the quality of weight loss from combination therapy. But the study also raises safety questions that can only be addressed with further data and studies.
Lilly’s gain in pain via Siteone takeout: Deals Report

4 days ago | biocentury.com | Paul Bonanos

ARTICLE | DealsPlus: Grin chooses Angelini as ex-North America partner for clinical asset to treat rare neurodevelopment disorder, and more By Paul Bonanos, Director of Biopharma Intelligence, and Meredith Durkin Wolfe, Director of ResearchMultibillion-dollar licensing and M&A deals attracted some of the biggest headlines this week, as did presentations at the American Society of Clinical Oncology meeting.
Lawsuit challenges layoffs at FDA, other HHS agencies

4 days ago | biocentury.com | Steve Usdin

ARTICLE | Politics, Policy & LawHHS Secretary Kennedy, DOGE officials relied on data they knew was flawed, suit states By Steve Usdin, Washington Editor Vid Desai was serving as FDA’s chief information officer on April 1 when he, along with about 10,000 other HHS employees, learned he’d been laid off. Like many others, the “reduction-in-force” notice Desai received was riddled with factual errors.
$9.1B Blueprint takeout gives Sanofi a growth driver in rare disease

5 days ago | biocentury.com | Paul Bonanos

ARTICLE | DealsPaul Hudson’s ninth billion-dollar deal as CEO gives pharma approved drug for systemic mastocytosis By Paul Bonanos, Director of Biopharma IntelligenceWith its purchase of Blueprint, long considered a prime M&A target, Sanofi will gain an approved drug for a rare immunological disorder as well as a pipeline that could address a broader swath of inflammatory diseases. The French pharma is paying $129 per share, or about $9.1 billion up front, to acquire Blueprint Medicines Corp.
With BMS-Biontech deal, value for cancer’s hottest target continues to climb

5 days ago | biocentury.com | Stephen Hansen

ARTICLE | Deals50/50 deal for PD-L1 x VEGF is worth $3.5B in upfront and non-contingent payments By Stephen Hansen, Director of Biopharma IntelligenceThe price for a PD-(L)1 x VEGF bispecific continues to climb, with Bristol Myers Squibb becoming the latest to enter the space under a deal with Biontech that’s worth at least $3.5 billion. And that’s only for rights to half of the program’s future revenues.
Wave of biopharma listings on East Asian markets: Public Equity Report

1 week ago | biocentury.com | Paul Bonanos

ARTICLE | FinancePlus: Taysha parlays FDA update into a rarity, a follow-on financing. And more By Jeff Cranmer, Executive Editor, and Paul Bonanos, Director of Biopharma IntelligenceA flurry of new listings in Hong Kong and South Korea is energizing Asia’s public equity markets. Tuesday marked the third listing of the year on the Hong Kong stock market’s 18A biotech chapter, with Pegbio Co. Ltd.
Industry races to counter Trump MFN threat

1 week ago | biocentury.com | Steve Usdin

ARTICLE | Politics, Policy & LawWhite House demanding 85% across-the-board drug price cuts; biopharma industry hopes to avoid catastrophic policies via alternative concessions By Steve Usdin, Washington Editor Biopharma leaders view President Donald Trump’s push for “most favored nation” drug pricing as a serious, urgent threat.
Atlas-incubated Vima launches with $60M: Venture Report

1 week ago | biocentury.com | Paul Bonanos

ARTICLE | FinancePlus: Grin raises cash as it strikes territorial deal with Angelini; a nine-figure round for Glycoera; and more By Paul Bonanos, Director of Biopharma IntelligenceA syndicate led by Atlas Venture launched a new start-up addressing movement disorders, while two other companies garnered nine-figure venture rounds to fuel their clinical plans.